Psychedelics


Revitalist Provides Summary of 2021, Reporting Patient Visits of 5,000, a 128% Increase From 2020

January 21st, 2022 - Ryan Allway

REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to recap the milestones the Company reached in the calendar year 2021. The Company has significantly scaled its operations during 2021, ending the year with seven clinics and providing approximately 5,000 patient treatments which represented a 128% increase […]

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

January 20th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has received a written response from the U.S. Food and […]

FSD Pharma Announces Launch of New Corporate Website

January 20th, 2022 - Ryan Allway

New Website Shares FSD’s Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders   TORONTO, January 20, 2022–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company“), a life sciences holding company dedicated to building a portfolio of assets and […]

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

January 19th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application, with the United Kingdom Medicines and Healthcare […]

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

January 18th, 2022 - Ryan Allway

Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care.   VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) […]

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001

January 18th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has obtained positive results from an in vivo oral bioavailability […]

Revitalist Credentials Clinics With the American Heart Association’s Certification of ACLS

January 18th, 2022 - Ryan Allway

REVITALIST LIFESTYLE AND WELLNESS LTD. (“ Revitalist ” or the “ Company ”) ( CSE: CALM ) ( OTC: RVLWF ) ( FSE: 4DO ) continues to advance skillsets in the psychedelic space broadening opportunities for research initiatives, allowing greater access and expansion to communities across the nation. Revitalist continues to broaden their value and recognition in the psychedelic space with providers trained in the advanced specialty […]

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

January 18th, 2022 - Ryan Allway

Expanding brand awareness and access to HaluGen’s Psychedelics Genetic Test Kit   Vancouver, British Columbia–(Newsfile Corp. – January 18, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction […]

PharmAla Biotech initiates research at the University of Arkansas for Medical Sciences

January 17th, 2022 - Ryan Allway

Proof-of-concept preclinical research begun on PharmAla’s patented novel drugs   VANCOUVER, BC, Jan. 17, 2022 /CNW/ – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA), a biotech company focused on the research, development and manufacturing of “psychedelic” pharmaceuticals in the MDXX class, is pleased to announce that the Company’s has initiated preclinical research on its […]

NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board

January 13th, 2022 - Ryan Allway

Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics   Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President […]

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

January 12th, 2022 - Ryan Allway

• Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe   NEW YORK, Jan. […]

Revitalist Increases Clinic Count to Nine With Closing of Florida Clinic Acquisition

January 12th, 2022 - Ryan Allway

  REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that it has executed an asset purchase agreement (“Agreement”) dated January 11, 2022, to acquire a Ketamine clinic located in Jacksonville, Florida (“Acquisition”). Revitalist had previously announced the Acquisition non-binding letter of intent on October […]

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

January 11th, 2022 - Ryan Allway

CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s […]

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

January 11th, 2022 - Ryan Allway

The Allowed Claims include Composition of FT-104, which is a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT   TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent […]

Cognetivity Neurosciences provides update on 2021 corporate achievements

January 11th, 2022 - Ryan Allway

Company poised for rapid expansion in 2022 after highly successful 2021, in which it secured commercial deployments across three continents, US FDA registration and multiple awards for innovation in AI   VANCOUVER, BC, Jan. 11, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) has provided an update on the […]

SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio

January 11th, 2022 - Ryan Allway

TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), announced that it has begun to examine the possibility of including psychedelic compounds as potential drug candidates for its intellectual property portfolio.     […]

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

January 11th, 2022 - Ryan Allway

Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and Communication   TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread […]

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

January 11th, 2022 - Ryan Allway

-Enrollment expected to begin in early 2022 – TORONTO, January 11, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™“, today announced that an Institutional Review Board (“IRB”) has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect […]

Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University

January 10th, 2022 - Ryan Allway

Research will focus on developing novel patentable psychedelics as potential drug candidates   TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased […]

Tripsitter Clinic Ltd. Announces Dual Listing on Frankfurt Stock Exchange, Marketing Agreement and Appointment of Richard Dolan as Director

January 10th, 2022 - Ryan Allway

TORONTO, Jan. 10, 2022 /PRNewswire/ – Tripsitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter Clinic” or the “Company“), a virtual clinic and tele-health company, is pleased to announce that the Company’s shares have been accepted for listing on the Frankfurt Stock Exchange (“FSE”) and commenced trading on January 5, 2022 under the symbol “UY0”.   TripSitter Clinic (CNW Group/TripSitter […]

Revitalist Opens its Eighth Clinic in Washington, D.C.

January 10th, 2022 - Ryan Allway

VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce it has opened its eighth psychedelic assisted psychotherapy (“PAP”) clinic located just outside of Washington, D.C. at 4833 Rugby Ave, STE 600, Bethesda, MD, 20814 (“Clinic”). “Bethesda has such a heavy military presence […]

PharmAla Biotech Announces Listing on the Canadian Securities Exchange

January 10th, 2022 - Ryan Allway

VANCOUVER, January 10, 2022 (GLOBE NEWSWIRE) – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA), a biotech company focused on the research, development and manufacturing of “psychedelic” pharmaceuticals in the MDXX class, is pleased to announce that the Company’s common shares have been approved for listing on the Canadian Securities Exchange (the “CSE”) […]

Revitalist to Participate in the H.C. Wainwright Bioconnect Conference in January 2022

January 7th, 2022 - Ryan Allway

REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that President & Chief Executive Officer, Kathryn Walker, will present virtually at the H.C. Wainwright Bioconnect Conference taking place on January 10-13, 2022. A webcast of Revitalist’s presentation will be available on-demand from Monday, January 10 th at […]

Psychedelic Therapies Evolving with Patented Improvements

January 6th, 2022 - Robin Lefferts

Psychedelic substances, such as psilocybin and DMT, have shown great promise in the treatment of a variety of psychiatric disorders, including depression, PTSD, and anxiety. The findings are driven by a wide range of studies, including from esteemed institutions such as Johns Hopkins and the Imperial College of London. In fact, the US National Institutes […]

3 Ways to Invest in Ketamine Clinics

January 6th, 2022 - Ryan Allway

Researchers believe that psychedelics may revolutionize mental health treatments, but FDA-approved psychedelics remain out of reach—with one exception. Unlike psilocybin or MDMA, ketamine is FDA-approved for anesthesia during medical procedures, opening the door to off-label use as a treatment for depression and other mental illnesses. With the FDA’s approval of Spravato and a growing body […]

Silo Wellness Appoints CEO Douglas K. Gordon to Board of Directors and Provides Corporation Updates

January 6th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – January 6, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Company’s Chief Executive Officer, Douglas K. Gordon, has been appointed as a director of the company. Mr. Gordon has led the company […]

Blackhawk’s MindBio Therapeutics to Develop Proprietary Drug Delivery Technology for Psychedelic Medicines

January 4th, 2022 - Ryan Allway

Vancouver, British Columbia – TheNewswire – January 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), is developing a proprietary technology and a new scientific method to objectively test the effectiveness and delivery of microdosing psychedelic […]

Filament Health Announces Health Canada Approval For Phase II Trial Administering New Psilocybin Microdose Formulation

January 4th, 2022 - Ryan Allway

  The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjects with persistent depressive disorder   VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Health Canada has approved a phase 2 clinical […]

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

January 4th, 2022 - Ryan Allway

– Last subject completed study in late 2021 with topline results expected in early 2022 –   – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal –   NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived […]

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

January 4th, 2022 - Ryan Allway

  Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan   TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), marks today one of the […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading